<DOC>
	<DOCNO>NCT01642472</DOCNO>
	<brief_summary>This phase III , multicentre , long-term open-label extension phase III study : Pearl IIIextension ( PGL09-027 ) . During Pearl III ( PGL09-026 ) subsequent Pearl III extension ( PGL09-027 ) , patient expose total 4 cycle daily 3month open-label treatment ulipristal acetate 10mg entering propose study Pearl extension 2 ( PGL11-024 ) . This propose study consist 4 consecutive course 3 month ( 84 day ) open label ulipristal acetate 10mg daily treatment separate drug free period .</brief_summary>
	<brief_title>PGL4001 Efficacy Assessment Reduction Symptoms Due Uterine Leiomyomata</brief_title>
	<detailed_description />
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Subject complete visit F Followup Pearl III extension study ( PGL09027 ) without significant deviation . Females childbearing potential advise practice nonhormonal method contraception . Subject history uterus surgery ( e.g . hysterectomy , myomectomy ) uterine artery embolization Pearl III extension ( PGL09027 ) afterwards would interfere study assessment . Subject take likely require treatment study drug permit study protocol . Subject lactating , positive pregnancy test study start plan pregnancy course study . Subject abnormal baseline finding , medical condition ( ) laboratory finding , opinion investigator , might jeopardise subject 's safety interfere study evaluation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>